BET in hematologic tumors:Immunity,pathogenesis,clinical trials and drug combinations
作者机构：Department of HematologyThe Affiliated Hospital of Southwest Medical UniversityLuzhouSichuan 646000China Department of HematologyLanzhou University Second HospitalLanzhouGansu 730000China
出 版 物：《Genes & Diseases》 (基因与疾病（英文）)
年 卷 期：2023年第10卷第6期
页 面：2306-2319页
核心收录：
学科分类：0710[理学-生物学] 1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：supported by grants from Cuiying Technology Innovation Project of Lanzhou University Second Hospital(China)(No.CY2017-ZD04 and CY2019-MS14) Commissioned Project of National Clinical Medicine Research Center for Hematological System Diseases(China)(No.2021WWA01) Talent Innovation and Entrepreneurship Project of Lanzhou,China(No.2020-RC-48).
主 题：BET BRD4 Clinical trials Hematologic tumors Immunity MYC
摘 要：The bromodomain and extra-terminal(BET)proteins act as“readersfor lysine acetylation and facilitate the recruitment of transcriptional elongation complexes.BET protein is associated with transcriptional elongation of genes such as c-MYC and BCL-2,and is involved in the regulation of cell cycle and apoptosis.Meanwhile,BET inhibitors(BETi)have regulatory effects on immune checkpoints,immune cells,and cytokine expression.The role of BET proteins and BETi in a variety of tumors has been studied.This paper reviews the recent research progress of BET and BETi in hematologic tumors(mainly leukemia,lymphoma and multiple myeloma)from cellular level studies,animal studies,clinical trials,drug combination,etc.BETi has a promising future in hematologic tumors,and future research directions may focus on the combination with other drugs to improve the efficacy.
维普期刊数据库